Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342869 | 1.00 | CYP17A1 (0.48) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL23630698 | 1.00 | CYP17A1 (0.48) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL8347257 | 1.00 | CYP17A1 (0.48) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL7196987 | 1.00 | CYP17A1 (0.48) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL6443645 | 0.89 | MEN1 (0.46) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL23378235 | 0.88 | AR (0.44) | MEN1KMT2ACYP19A1CYP3A4LMNA | |
| SCHEMBL6436575 | 0.87 | CYP3A4 (0.46) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL5897208 | 0.87 | CYP3A4 (0.46) | CYP17A1MEN1KMT2ACYP19A1CYP3A4 | |
| SCHEMBL11329429 | 0.86 | AR (0.42) | MEN1KMT2ACYP19A1CYP3A4LMNA | |
| SCHEMBL11329447 | 0.86 | AR (0.42) | MEN1KMT2ACYP19A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | disclosed |
| US-5908944-A | COPPER COMPOUND CATALYST | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-01 | — | — | US | disclosed |
| US-5908945-A | COPPER COMPOUND AND SILYL REAGENT AS CATALYSTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-01 | — | — | US | disclosed |
| US-5804576-A | CANCER PREVENTIVE AGENTS, ANTI-OBESITY AGENTS, TREATMENT OF DIABETES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5714481-A | ADMINISTERING TO MAMMALIAN HOST A GLUCOSE-6-PHSOPHATE DEHYDROGENASE INHIBITOR, ANTICARCINOGENIC, ANTIOBASITY, ANTI-HYPERGLYCEMIC, ANTIAGING, ANTICHOLESTEROL AND ANTI-AUTOIMMUNE AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0691974-B1 | ALKYLATING AGENT AND 1,4-ADDITION PROCESS OF AN ALKYL GROUP ONTO AN ALPHA, BETA-UNSATURATED KETONE COMPOUND | SCHERING AG (DE) | 1997-05-07 | — | — | EP | disclosed |
| EP-0534582-B1 | Methylation or ethylation agent and process for an 1,4-addition of a methyl- or ethylgroup to an alpha, beta-insaturated ketogroup | SCHERING AG (DE) | 1997-01-08 | — | — | EP | disclosed |
| WO-1993006066-A1 | METHYLATING OR ETHYLATING AGENT AND PROCESS FOR 1,4-ADDING A METHYL OR ETHYL GROUP TO AN α,β-UNSATURATED KETO COMPOUND __ | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-04-01 | — | — | WO | disclosed |
| EP-0534582-A1 | Methylation or ethylation agent and process for an 1,4-addition of a methyl- or ethylgroup to an alpha, beta-insaturated ketogroup | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-03-31 | — | — | EP | disclosed |
| EP-0133995-A2 | Steroids and therapeutic compositions containing same | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1985-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | CYP17A1 4/4885MEN1 580/4885KMT2A 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.